Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-17-0171
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma

Cancer Discovery
Oncology
2019English

MYC Inhibition Plus P53 Stabilization Targets Leukemic Stem Cells

Cancer Discovery
Oncology
2016English

HDAC4 Degradation Mediates HDAC Inhibition-Induced Protective Effects Against Hypoxia/Reoxygenation Injury

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2015English

N-Myc Targets

Genome Biology
2001English

mTOR Complex 2 Targets Akt for Proteasomal Degradation via Phosphorylation at the Hydrophobic Motif

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2011English

False HDAC Inhibition by Aurone Compound

Chemical and Pharmaceutical Bulletin
MedicineDrug DiscoveryChemistry
2016English

Combinatorial Antitumor Effect of HDAC and the PI3K-Akt-mTOR Pathway Inhibition in a Pten Defecient Model of Prostate Cancer

Oncotarget
Oncology
2013English

BRK Targets Dok1 for Ubiquitin-Mediated Proteasomal Degradation to Promote Cell Proliferation and Migration

PLoS ONE
Multidisciplinary
2014English

mTOR-Inhibition Neue Standardtherapie?

Best Practice Onkologie
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy